Navigation Links
Diamyd(R) Phase III Study Approved for Younger Patients in the US
Date:6/8/2009

STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body's insulin-producing cells, thereby preserving the body's own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes.

The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study.

"This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world's largest diabetes conference, the ADA's 69th Scientific Sessions, which is currently ongoing in New Orleans."

The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011.

Diamyd Medical is represented at booth #2431 at the ADA's 69th Scientific Se
'/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
4. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
5. Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
8. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
9. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... , May 20, 2013 Today, at the ... Francisco , James McGough , ... at the Semel Institute for Neuroscience and Human Behavior ... Medicine at the University of California Los Angeles (UCLA), ... and Adolescent Psychopharmacology and ADHD at UCLA, presented the ...
(Date:5/20/2013)... 2013 With bed bugs' presence come problems ... bed bugs need to be eliminated, one must make sure ... person's health. And so to help bed bug sufferers get ... rid of bed bugs without using harmful pesticides. In ... it called Bed Bug Bully. , According to My Cleaning ...
(Date:5/20/2013)... 20, 2013 Rhythm announced today the results ... the company,s novel ghrelin agonist for the treatment of ... demonstrated that RM-131 significantly accelerates early gastric emptying and ... patients with diabetic gastroparesis. The findings were presented at ... Orlando and recently published in Clinical ...
Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... Transgene,(Euronext Paris: FR0005175080) announces promising preliminary data from,the ... as an adjunct to first line chemotherapy in ... This on-going trial is a randomized, open label ... TG4010 in combination with cisplatin and,gemcitabine compared to ...
... full year and fourth quarter 2007 preservation services and, ... to approximately $93.7 million for the year and ... 10 CryoLife, Inc. (NYSE: CRY ),a biomaterials, ... services and product revenues for 2007 were,approximately $93.7 million ...
... Berman Sobol Shapiro LLP,( http://www.hbsslaw.com/cellcyte.htm ) today ... CellCyte (OTC Bulletin Board: CCYG) for potential,violations ... after CellCyte,s shares plunged 55 percent,after news ... Gary,Reys, educational and professional credentials., CellCyte,s ...
Cached Biology Technology:Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 2CryoLife Announces Record Preservation Services and Product Revenues for 2007 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 4Hagens Berman Sobol Shapiro Investigating CellCyte 2
(Date:5/17/2013)... residents of all ages will celebrate the science ... on our daily lives during the inaugural Atlanta ... and educators from local museums, corporations, K-12 schools ... 40 different events for children and adults at ... http://atlantasciencefestival.org . , The annual Atlanta Science ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... - Bacteria are able to build camouflaged homes for themselves inside ... cellular process. , Purdue University ... from the bacteria Legionella pneumophila , which causes Legionnaires disease, ... the cell for use in building and disguising a large structure ...
... This press release is available in French . ... 19th -Century Montreal in two major ways, according to research ... infants from food and water contaminated by fecal bacteria, while ... the health of mothers as well as their subsequent children. ...
... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab), through a ... a special line of human breast cells, have found ... ionizing radiation, cancer risks may not be directly proportional ... biological damage from ionizing radiation - the linear-no-threshold hypothesis ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Breastfeeding saved babies in 19th century Montreal 2Breastfeeding saved babies in 19th century Montreal 3New take on impacts of low dose radiation 2New take on impacts of low dose radiation 3New take on impacts of low dose radiation 4
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Biology Products: